📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. (2020)

First Author: Pushpakom S
Attributed to:  Renewal of the Network of Hubs for Trials Methodology Research. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciz589

PubMed Identifier: 31425580

Publication URI: http://europepmc.org/abstract/MED/31425580

Type: Journal Article/Review

Volume: 70

Parent Publication: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Issue: 10

ISSN: 1058-4838